25. Progressive multifocal leukoencephalopathy Clinical trials / Disease details
Clinical trials : 26 / Drugs : 35 - (DrugBank : 22) / Drug target genes : 8 - Drug target pathways : 37
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2012-000725-41-GB (EUCTR) | 22/01/2013 | 04/09/2012 | A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy | A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy. - INVICTUS | HIV-infected patients with Progressive Multifocal Leukoencephalopathy MedDRA version: 15.0;Level: PT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy;System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02] | Product Name: Recombinant human interleukin-7 Product Code: CYT107 INN or Proposed INN: N/A Other descriptive name: Recombinant human interleukin-7 | Cytheris S.A. | NULL | Not Recruiting | Female: yes Male: yes | 57 | Phase 2 | United States;European Union;Spain;Italy;Switzerland;United Kingdom | ||
| 2 | EUCTR2012-000725-41-ES (EUCTR) | 12/12/2012 | 14/09/2012 | A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy | A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy. - INVICTUS | HIV-infected patients with Progressive Multifocal Leukoencephalopathy MedDRA version: 15.0;Level: PT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy;System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02] | Product Name: Recombinant human interleukin-7 Product Code: CYT107 INN or Proposed INN: N/A Other descriptive name: Recombinant human interleukin-7 | Cytheris S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 57 | Phase 2 | United States;European Union;Spain;United Kingdom;Switzerland | ||
| 3 | EUCTR2012-000725-41-IT (EUCTR) | 08/11/2012 | 11/12/2012 | A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy | A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy - INVICTUS | HIV-infected patients with Progressive Multifocal Leukoencephalopathy MedDRA version: 14.1;Level: SOC;Classification code 10021881;Term: Infections and infestations;System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02] | Product Name: Recombinant human interleukin-7 Product Code: CYT107 Other descriptive name: Recombinant human interleukin-7 | CYTHERIS | NULL | Not Recruiting | Female: yes Male: yes | 57 | Phase 2 | United States;Spain;United Kingdom;Switzerland;Italy |